RCS - PureTech Health PLC - PRTC to Present at Cowen and Leerink Conferences

Puretech HealthAnnouncement

27/02/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240227:nRSa5213Ea&default-theme=true

RNS Number : 5213E  PureTech Health PLC  27 February 2024

27 February 2024

PureTech Health plc

 

PureTech to Present at Two Upcoming Investor Conferences

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to changing the lives of patients with devastating diseases, today
announced that members of the management team will participate at two upcoming
investor conferences. Webcasts of the presentations will be available at
https://investors.puretechhealth.com (https://investors.puretechhealth.com) .

 

TD Cowen 44th Annual Health Care Conference

Presenters: Daphne Zohar, Founder and Chief Executive Officer, and Eric
Elenko, Ph.D., Chief Innovation Officer

Date: Tuesday, March 5, 2024

Time: 1:30 p.m. EST

 

Leerink Partners Global Biopharma Conference

Presenters: Bharatt Chowrira, Ph.D., J.D., President, and Eric Elenko, Ph.D.,
Chief Innovation Officer

Date: Wednesday, March 13, 2024

Time: 10:40 a.m. EDT

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 28 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both US
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to our upcoming presentation at TD
Cowen's 44th Annual Health Care Conference, the Leerink Partners Global
Biopharma Conference, and our future prospects, developments and strategies.
The forward-looking statements are based on current expectations and are
subject to known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under the caption
"Risk Factors" in our Annual Report on Form 20-F for the year ended December
31, 2022 filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

 Contact:

 PureTech

 Public Relations

 publicrelations@puretechhealth.com

 Investor Relations

 IR@puretechhealth.com

 EU Media

 Ben Atwell, Rob Winder

 +44 (0) 20 3727 1000

 ben.atwell@FTIconsulting.com

 U.S. Media

 Nichole Bobbyn

 +1 774 278 8273

 nichole@tenbridgecommunications.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGZZGVFGDZZ